Follikuláris limfóma: vizsgálatok itt: Dél-Korea
15 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.
- 2. fázisTaking peopleEvaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
- Where
- Seongnam-si, Seoul
- Életkor
- 18 év and over
- People
- 130 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06806033 · EU 2024-516791-15-00 - 1/2. fázisTaking peopleA Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
- Where
- Seoul
- Életkor
- 18 év and over
- People
- 280 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07519772 · EU 2025-523005-15-00 - 2/3. fázisTaking peopleA Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
- Where
- Seoul
- Életkor
- 18 év and over
- People
- 960 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07634471 · EU 2025-522777-10-00 - 1. fázisTaking peopleA Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- Where
- Seoul
- Életkor
- 18 év and over
- People
- 215 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07101328 · EU 2025-524180-20-00 - 3. fázisTaking peopleA Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
- Where
- Busan, Goyang-si, Jeonnam, Seoul
- Életkor
- 18 év to 130 év
- People
- 1018 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06549595 · EU 2023-510098-33-01 - 1. fázisTaking peopleA Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
- Where
- Daejeon, Seongnam, Seoul
- Életkor
- 18 év and over
- People
- 453 worldwide
- Run by
- Pfizer
See details and how to joinNCT03460977 · EU 2023-509179-18-00 - 2. fázisTaking peopleSurovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
- Where
- Seoul
- Életkor
- 18 év and over
- People
- 270 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06526793 · EU 2023-505789-27-00 - 3. fázisTaking peopleA Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
- Where
- Busan, Daegu, Incheon, Jeonju, Seoul, Suwon, Ulsan
- Életkor
- 18 év and over
- People
- 580 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT06149286 · EU 2022-503092-28-00 - 3. fázisTaking peopleA Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
- Where
- Busan, Daegu, Goyang-si, Jeonju, Seoul, Suwon
- Életkor
- 18 év and over
- People
- 822 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT06091254 · EU 2022-502660-20-00 - 1/2. fázisTaking peopleA Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Where
- GangnamGu, SeochoGu, SeodaemunGu, Seogu, Seoul, SongpaGu
- Életkor
- 18 év and over
- People
- 689 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT05006716 · EU 2022-502157-33-00 - No phaseTaking peopleLong-term Follow up Local Registry Study of Kymriah in South Korea
- Where
- Bundang Gu, Busan, Gyeonggi-do, Incheon, Jeollanam, Seongnam-si, Seoul, Ulsan
- Életkor
- 0 év to 100 év
- People
- 500
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06785818 - 1/2. fázisTaking peopleStudy of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients
- Where
- Seoul
- Életkor
- 19 év and over
- People
- 91
- Run by
- Curocell Inc.
See details and how to joinNCT04836507 - 3. fázisTaking peopleA Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
- Where
- Seoul
- Életkor
- 18 év and over
- People
- 400 worldwide
- Run by
- Celgene
See details and how to joinNCT06911502 · EU 2024-519152-82-00 - 1/2. fázisTaking peopleStudy of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients
- Where
- Seoul
- Életkor
- 19 év and over
- People
- 98
- Run by
- TICAROS Co., Ltd.
See details and how to joinNCT07473167 - No phaseCsak meghívásosWatch and Wait or Worry and Wait in Indolent Lymphoma
- Where
- Seoul
- Életkor
- 19 év and over
- People
- 250
- Run by
- Seoul National University Hospital
See details and how to joinNCT07173790